In this this real-world study using a global federated dataset, we aimed to evaluate the impact of SGLT2i and GLP1-ra therapy on the risk of diabetic retinopathy and DMO in individuals with type 2 diabetes taking insulin. Here, INS is linked to type 2 diabetes mellitus.